Multiple Myeloma Canada is a 4-star charity. It has an A- results reporting grade, which is above average. Its overhead spending is within Ci’s reasonable range, and it has reserve funds to cover one year and three months of its annual program costs.

Founded in 2005, Multiple Myeloma Canada (Myeloma Canada) aims to improve the lives of Canadians affected by myeloma. It also seeks to accelerate access to care and support the pursuit of a cure and prevention. Myeloma is the second most common form of blood cancer. It involves the abnormal behaviour and uncontrolled growth of plasma cells. The charity reports that approximately 11 people are diagnosed with myeloma each day. Myeloma Canada has five main programs: Research, Community Empowerment, Awareness and Communication, Patient and Education programs, and Access and Advocacy.

In 2023, Myeloma Canada spent $1.0m (33% of program spending) on Research. The charity funded 16 research projects and 12 science projects in 2023. Myeloma Canada partnered with Pfizer in 2023 to award four grants totalling $266k. These grants supported projects to advance the quality of care. Myeloma Canada hosted the 14th annual Myeloma Canada Scientific Roundtable in 2023. The roundtable had over 100 attendees from nine provinces. It featured four clinical trial updates, nine presentations from industry leaders, and 11 academic presentations.

Myeloma Canada spent $613k (19% of program spending) on Community Empowerment in 2023. The charity had 48 local support groups in 2023, including six new local groups. It also offered six virtual support groups and two peer-to-peer support programs. In 2023, the charity hosted seven meet-and-greets.

Myeloma Canada spent $542k (17% of program spending) on Awareness and Communication in 2023. For Multiple Myeloma Awareness Month (MMAM), the charity reports that it produced over ten unique social media posts and messages. It displayed an eight-second static billboard ad on 18 screens across 400-series highways in the GTA. 22 buildings and monuments were lit red in recognition of MMAM in 2023.

Myeloma Canada spent $383k (12% of program spending) on Patient and Education programs in 2023. Myeloma Canada held 14 information webinars with 3,000 views in 2023. It also released three information videos. My Life My Myeloma is an online resource centre that gives people with myeloma tools for their healthcare journey. In 2023, it had 1,478 users.

Myeloma Canada spent $137k (4% of program spending) on Access and Advocacy in 2023. The charity participated in two legislative action days and eight consultations. It also submitted ten surveys and patient input records for new drug therapies.

The charity spent $472k (15% of program spending) on Knowledge Transfer in 2023. Ci assumes Knowledge Transfer spending is spread across the charity’s five main programs.

In 2023, Multiple Myeloma Canada received $3.5m in donations and special events revenue. Administrative costs are 17% of total revenue (excluding investment income) and fundraising costs are 10% of donations. Overhead spending is 27%, which is within Ci’s reasonable range. For every dollar donated, 73 cents are available for the cause. In 2023, Myeloma Canada spent $3.2m on its programs (87% of total revenue).

In 2023, Myeloma Canada had a deficit of ($349k) and spent $6k on capital expenditures.

At the end of 2023, Myeloma Canada had $4.0m in reserve funds (cash and investments). This is enough to cover 127% or one year and three months of its annual program costs.

This charity profile is an update that was sent to Multiple Myeloma Canada for review. Changes and edits may be forthcoming.

Updated August 14^th, 2024 by Thea Clark.